Gwladys Gernoux

Dr. Gwladys Gernoux

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2020 in New England Journal of Medicine
Verified
Journal Article
Closed access
CMChristian Mueller
Christian Mueller
JBJames D. Berry
James D. Berry
DMDiane M. McKenna-Yasek
Diane M. McKenna-Yasek
Gwladys GernouxGwladys Gernoux
Gwladys Gernoux
MOMargaret A. Owegi
Margaret A. Owegi
RBRobert H. Brown
Robert H. Brown
Two patients with familial amyotrophic lateral sclerosis (ALS) and mutations in the gene encoding superoxide dismutase 1 (SOD1) were treated with a single intrathecal infusion of adeno-associated virus encoding a microRNA targeting SOD1. In Patient 1, SOD1 levels in spinal cord tissue as analyzed on autopsy were lower than corresponding levels in untreated patients with SOD1-mediated ALS and in healthy controls. Levels of SOD1 in cerebrospinal fluid were transiently and only slightly lower in Patient 1 but were not affected in Patient 2. In Patient 1, meningoradiculitis developed after the infusion; Patient 2 was pretreated with immunosuppressive drugs and did not have this complication. Patient 1 had transient improvement in the strength of his right leg, a measure that had been relatively stable throughout his disease course, but there was no change in his vital capacity. Patient 2 had stable scores on a composite measure of ALS function and a stable vital capacity during a 12-month period. This study showed that intrathecal microRNA can be used as a potential treatment for SOD1-mediated ALS.

2 August 2019 in Nature Biotechnology
Verified
Journal Article
Open access
JAJulia F. Alterman
Julia F. Alterman
BGBruno M. D. C. Godinho
Bruno M. D. C. Godinho
MHMatthew R. Hassler
Matthew R. Hassler
CFChantal M. Ferguson
Chantal M. Ferguson
DEDimas Echeverria
Dimas Echeverria
AKAnastasia Khvorova
Anastasia Khvorova
Sustained silencing of gene expression throughout the brain using small interfering RNAs (siRNAs) has not been achieved. Here we describe an siRNA architecture, divalent siRNA (di-siRNA), that supports potent, sustained gene silencing in the central nervous system (CNS) of mice and nonhuman primates following a single injection into the cerebrospinal fluid. Di-siRNAs are composed of two fully chemically modified, phosphorothioate-containing siRNAs connected by a linker. In mice, di-siRNAs induced the potent silencing of huntingtin, the causative gene in Huntington's disease, reducing messenger RNA and protein throughout the brain. Silencing persisted for at least 6 months, with the degree of gene silencing correlating to levels of guide strand tissue accumulation. In cynomolgus macaques, a bolus injection of di-siRNA showed substantial distribution and robust silencing throughout the brain and spinal cord without detectable toxicity and with minimal off-target effects. This siRNA design may enable RNA interference-based gene silencing in the CNS for the treatment of neurological disorders.

10 February 2022 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
TFTerence R Flotte
Terence R Flotte
OCOguz Cataltepe
Oguz Cataltepe
APAjit Puri
Ajit Puri
ABAna Rita Batista
Ana Rita Batista
RMRichard Moser
Richard Moser
MSMiguel Sena-Esteves
Miguel Sena-Esteves

28 December 2015 in Human Gene Therapy
Verified
Journal Article
Open access
FBFlorie Borel
Florie Borel
Gwladys GernouxGwladys Gernoux
Gwladys Gernoux
BCBrynn Cardozo
Brynn Cardozo
JMJake P. Metterville
Jake P. Metterville
GCGabriela T. Cabrera
Gabriela T. Cabrera
CMChristian Mueller
Christian Mueller
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease; survival in ALS is typically 3–5 years. No treatment extends patient survival by more than three months. Approximately 20% of familial ALS and 1–3% of sporadic ALS patients carry a mutation in the gene encoding superoxide dismutase 1 ( SOD1 ). In a transgenic ALS mouse model expressing the mutant SOD1 G93A protein, silencing the SOD1 gene prolongs survival. One study reports a therapeutic effect of silencing the SOD1 gene in systemically treated adult ALS mice; this was achieved with a short hairpin RNA, a silencing molecule that has raised multiple safety concerns, and recombinant adeno-associated virus (rAAV) 9. We report here a silencing method based on an artificial microRNA termed miR-SOD1 systemically delivered using adeno-associated virus rAAVrh10, a serotype with a demonstrated safety profile in CNS clinical trials. Silencing of SOD1 in adult SOD1 G93A transgenic mice with this construct profoundly delayed both disease onset and death in the SOD1 G93A mice, and significantly preserved muscle strength and motor and respiratory functions. We also document that intrathecal delivery of the same rAAVrh10-miR-SOD1 in nonhuman primates significantly and safely silences SOD1 in lower motor neurons. This study supports the view that rAAVrh10-miR-SOD1 merits further development for the treatment of SOD1 -linked ALS in humans.

1 June 2017 in Molecular Therapy
Verified
Journal Article
Open access
CMChristian Mueller
Christian Mueller
Gwladys GernouxGwladys Gernoux
Gwladys Gernoux
AGAlisha M. Gruntman
Alisha M. Gruntman
FBFlorie Borel
Florie Borel
EREmer P. Reeves
Emer P. Reeves
TFTerence R Flotte
Terence R Flotte
Alpha-1 antitrypsin deficiency is a monogenic disorder resulting in emphysema due principally to the unopposed effects of neutrophil elastase. We previously reported achieving plasma wild-type alpha-1 antitrypsin concentrations at 2.5%-3.8% of the purported therapeutic level at 1 year after a single intramuscular administration of recombinant adeno-associated virus serotype 1 alpha-1 antitrypsin vector in alpha-1 antitrypsin deficient patients. We analyzed blood and muscle for alpha-1 antitrypsin expression and immune cell response. We also assayed previously reported markers of neutrophil function known to be altered in alpha-1 antitrypsin deficient patients. Here, we report sustained expression at 2.0%-2.5% of the target level from years 1-5 in these same patients without any additional recombinant adeno-associated virus serotype-1 alpha-1 antitrypsin vector administration. In addition, we observed partial correction of disease-associated neutrophil defects, including neutrophil elastase inhibition, markers of degranulation, and membrane-bound anti-neutrophil antibodies. There was also evidence of an active T regulatory cell response (similar to the 1 year data) and an exhausted cytotoxic T cell response to adeno-associated virus serotype-1 capsid. These findings suggest that muscle-based alpha-1 antitrypsin gene replacement is tolerogenic and that stable levels of M-AAT may exert beneficial neutrophil effects at lower concentrations than previously anticipated.

1 June 2018 in Human Gene Therapy
Verified
Journal Article
Closed access
EPEdith L. Pfister
Edith L. Pfister
NDNatalie DiNardo
Natalie DiNardo
EMErica Mondo
Erica Mondo
FBFlorie Borel
Florie Borel
FCFaith Conroy
Faith Conroy
NANeil Aronin
Neil Aronin
Huntington's disease (HD) is a fatal neurodegenerative disease caused by a genetic expansion of the CAG repeat region in the huntingtin (HTT) gene. Studies in HD mouse models have shown that artificial miRNAs can reduce mutant HTT, but evidence for their effectiveness and safety in larger animals is lacking. HD transgenic sheep express the full-length human HTT with 73 CAG repeats. AAV9 was used to deliver unilaterally to HD sheep striatum an artificial miRNA targeting exon 48 of the human HTT mRNA under control of two alternative promoters: U6 or CβA. The treatment reduced human mutant (m) HTT mRNA and protein 50–80% in the striatum at 1 and 6 months post injection. Silencing was detectable in both the caudate and putamen. Levels of endogenous sheep HTT protein were not affected. There was no significant loss of neurons labeled by DARPP32 or NeuN at 6 months after treatment, and Iba1-positive microglia were detected at control levels. It is concluded that safe and effective silencing of human mHTT protein can be achieved and sustained in a large-animal brain by direct delivery of an AAV carrying an artificial miRNA.